Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes

Current Diabetes Reports
Gül BahtiyarAlan Sacerdote

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have positive effects on weight loss, blood pressure, hyperlipidemia, and glycemic control. They exhibit a broad range of effects on the cardiovascular system that are independent of changes in blood glucose. Cardiovascular outcome trials have demonstrated safety of GLP-1 RAs but results for cardiovascular efficacy were varied. The aim of the present review is the assessment of the effects of GLP-1 RAs on cardiovascular risk factors, and major cardiovascular events. Use of GLP-1 RAs was associated with relative risk reduction in cardiovascular mortality and all-cause mortality with no significant differences for the incidence of severe hypoglycemia, pancreatitis, pancreatic cancer, or medullary thyroid cancer when compared to placebo. Although there are differences between individual medications with respect to their effects on cardiovascular events, GLP-1 RAs offer a favorable risk-benefit profile. The present review confirms the cardiovascular safety and efficacy vs placebo of GLP-1 RAs in patients with type 2 diabetes at moderate-to-high atherosclerotic cardiovascular risk without significant side effects. Although professional guidelines recommend metformin as the sole f...Continue Reading

References

May 15, 2003·Endocrinology·Robert GrosMansoor Husain
Jun 5, 2003·Journal of Hypertension·Ming YuRichard J Roman
Feb 21, 2006·The Journal of Pharmacology and Experimental Therapeutics·Tingcun ZhaoRichard P Shannon
May 11, 2006·Journal of Hypertension·Paola Primatesta, Neil R Poulter
Mar 11, 2010·Diabetes Care·John B BuseUNKNOWN DURATION-1 Study Group
Mar 25, 2010·Diabetes Care·John B BuseUNKNOWN Liraglutide Effect Action in Diabetes-6 Study Group
Oct 19, 2010·American Journal of Physiology. Heart and Circulatory Physiology·Dick H J ThijssenDaniel J Green
Apr 7, 2011·The Journal of Clinical Hypertension·Amanda N Long, Samuel Dagogo-Jack
May 6, 2011·Diabetes Care·Simona Cernea, Itamar Raz
Sep 17, 2011·European Heart Journal·Jacob LønborgThomas Engstrøm
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub
Apr 13, 2012·Circulation. Cardiovascular Interventions·Jacob LønborgThomas Engstrøm
Aug 2, 2013·Diabetes Care·Edoardo MannucciPaolo Pozzilli
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Jul 12, 2014·The New England Journal of Medicine·UNKNOWN HPS2-THRIVE Collaborative GroupJane Armitage
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Oct 16, 2015·Journal of Atherosclerosis and Thrombosis·Tomohisa NezuMasayasu Matsumoto
Oct 30, 2015·Diabetes, Obesity & Metabolism·Sten Madsbad
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Apr 28, 2016·Endocrinology and Metabolism·Yu Mi Kang, Chang Hee Jung

❮ Previous
Next ❯

Citations

Jul 20, 2019·Therapeutic Advances in Chronic Disease·Olusola F OnoviranMukaila A Raji
Jul 19, 2019·Clinical Drug Investigation·Katherine A Lyseng-Williamson
Mar 24, 2020·The World Journal of Men's Health·Young Jin Tak, Sang Yeoup Lee
Jun 12, 2020·Therapeutic Advances in Endocrinology and Metabolism·Kaylee WoodardDaniel S Hsia
Jan 8, 2021·Current Obesity Reports·Young Jin Tak, Sang Yeoup Lee
Feb 2, 2021·Journal of Diabetes and Metabolic Disorders·Mandana HasanzadHamid Reza Aghaei Meybodi
May 29, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Wen-Ling Chou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.